US FDA panel calls for clarity on duration of bone drug use, but sets no cutoff
This article was originally published in SRA
Executive Summary
Advisors to the US Food and Drug Administration deliberating over the safety and effectiveness of using bisphosphonates to prevent and treat osteoporosis have voted (17-6) in favour of clarifying the duration of use on the labels of such drugs. The recommendation, made on 9 September, however, fell short of specifying a particular limit1,2.